InventisBio Co., Ltd. today announced promising results from a Phase 2 clinical trial of D-2570, an oral selective inhibitor of the TYK2 kinase, in patients with moderate to severe ...
Outcomes study will assess mortality and hospitalization in patients treated with Vafseo compared to current standard of care "We look forward to begin treating CKD anemia patients on dialysis with ...